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INTRODUCTION 
Inflammatory bowel disease (IBD) is a collective name of idiopathic diseases causing chronic 
inflammation in the gastrointestinal tract, of which Crohn’s disease (CD) and ulcerative colitis 
(UC) are the most common [1]. Unclassified IBD (IBDU) is diagnosed in patients for whom 
the clinical decision is uncertain. IBD has a prevalence exceeding 0.3% in western countries, 
and the frequency has been increasing in recently industrialized countries located in Africa, 
Asia, and South America since 1990 [2, 3]. No defined pathogenesis has been established for 
IBD, but it is believed to derive from several environmental factors and particularly an 
inappropriate immune response against the gut microbiome in a host, who is genetically prone 
to IBD [4, 5]. 
There is no absolute cure for IBD, but the inflammation can be controlled with medication that 
induce and maintain remission. The treatment can for example consist of 5-aminosalicylic acid 
(5-ASA), and in some cases even corticosteroids [6]. Approximately 10–15% of the IBD patient 
receiving this treatment need further treatment to maintain the remission [7]. TNF-α is a 
proinflammatory cytokine, which is found to be associated with both CD and UC [8]. Infliximab 
is a chimeric monoclonal antibody, which binds to TNF-α thereby blocking its activity. 
Infliximab is a biological drug given to IBD patients to successfully maintain remission [9]. 
However, 10–40% of the CD patients and approximately 50% of the UC patients receiving 
infliximab do not respond to the medication. Additionally, up to 40% of the responders lose 
response over time [10].  
The human body serves as host for a variety of different microorganisms, and our intestinal 
tract alone is colonized with up to 1014 microorganisms, of which the majority resides in the 
colon [11]. These microorganisms make up the human microbiome and include bacteria, 
archaea, fungi, and viruses. Next-generation sequencing technology has enabled the unravelling 
of complex symbiosis between the microbiome and the host. In the human microbiota, bacteria 
are by far the most abundant, with approximately 1011 bacterial cells compared to 105 fungal 
cells per gram of feces [12]. Naturally, this has led research to a focus on the bacteria. However, 
the fungal cells are 100-fold larger in volume compared to bacterial cells, signifying that these 
cannot be compared only by cell counts [13]. This suggests the importance of studying the 
mycobiota, meaning the fungal communities included in the microbiome. 
There are multiple antibodies against several structures found on bacteria and fungi. Of these, 
the anti- Saccharomyces cerevisiae antibody (ASCA) is one of the most studied and is used as 
a serological marker for CD. ASCA is an antibody against oligomannosides in the cell wall of 
bakers’ yeast [14], S. cerevisiae, which also is observed to be a member of the human gut 
mycobiota. 
Calprotectin is a protein dimer of the subunits S100A8 and S100A9 and is present on the surface 
of macrophages and monocytes. The protein is considered to be an inflammatory marker, as its 
production increases during inflammation. Fecal calprotectin is a marker for IBD, and it is 
therefore used for the determining the disease activity [15]. Serum calprotectin is considered to 
derive from circulating leukocytes, rather than from the intestinal tract. According to this, high 
serum calprotectin levels may correlate with a more systematic inflammation, and not the local 
inflammation that is observed in IBD. Currently, few studies have taken serum calprotectin into 
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consideration when studying IBD, and no significant association has been observed between 
the fecal calprotectin and the serum calprotectin concentrations [16]. 
In this study, the aim was to discover new predictive markers for the drug response against 
infliximab in IBD patients, as no reliable diagnostic markers are available to this day. This was 
achieved by first characterizing the gut mycobiota in prospective IBD patients. The gut 
mycobiota composition was determined by using an internal transcribed spacer 1 (ITS1) rRNA 
MiSeq sequencing analysis of fungal DNA from stool samples collected before start of 
infliximab and throughout one year of treatment. In the sequencing, the ITS1 and ITS2 regions 
were targeted, amplifying the conserved, non-coding ITS1 region of fungal DNA, which 
previously has been used for this purpose [17]. As additional data supporting the study, the 
concentration of ASCA IgG and IgA were measured from baseline serum samples, and 
calprotectin concentrations were measured from baseline and twelve weeks post infliximab 
serum samples in prospective IBD patients using ELISA. As primary antibody in the 
calprotectin ELISA assay, 3406 was used in one combination and 3407 in the other. 3406 binds 
to the S100A8 subunit of the calprotectin protein complex and 3407 binds to the S100A8/A9 
complex. As secondary antibody 3407 was used for both combinations. Thus, the 3407-3407 
combination target the S100A8/A9 protein complex and the 3406-3407 target the S100A8 and 
S100A8/A9 complex. The calprotectin concentrations determined from serum samples were 
compared with those measured from stool samples of prospective IBD patients in connection 
with samples collection, to determine whether the serum calprotectin could be used as a similar 
inflammatory marker as fecal calprotectin is used. Finally, the MiSeq sequencing data was 
analyzed together with the additional data to find predictive markers for the drug response 
against infliximab. 
METHODS 
Study design and subjects 
The cohort consisted of patients aged 13–64 years at the Department of Gastroenterology, 
Helsinki University Hospital, suffering from ulcerative colitis or Crohn’s disease, for whom 
infliximab therapy was being initiated. The IBD patients had previously been diagnosed 
unresponsive to regular treatment with corticosteroids and immunosuppressants and the 
infliximab medication was therefore given to maintain remission. The response diagnosis to 
infliximab used in this study was assigned at twelve weeks post infliximab therapy, when the 
first response diagnosis is determined. Participants for the cohort were recruited during 2018 
and 2019. Stool and serum samples were collected before starting infliximab therapy and two, 
six, and twelve weeks, as well as one year after the start of medication.  
DNA extraction 
The fecal samples were collected and transported to the research facilities within approximately 
8 hours, where they were stored at -80 ˚C until analysis. The DNA was extracted from stool 
samples using the repeated bead beating (RBB) method, which has previously been 
recommended [18]. The RBB method was developed for DNA extraction from bovine feces 
[19] and has been modified to extraction from rumen [20, 21]. Additional optimization has later 
been done for extraction of DNA from fecal samples [18]. In this study, the extraction method 
was further validated by comparison of the RBB method with and without the addition of 
proteinase K, which is included in most extraction methods used elsewhere [17]. The DNA 
extraction protocol used was the method optimized for fecal DNA extraction [18]. Briefly, the 
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fecal samples were partially thawed, weighed, and PBS was added to each sample. The samples 
were vortexed and transferred to bead beating tubes containing beads. After the addition of lysis 
buffer (1M Tris-HCl pH 8), the samples underwent the RBB procedure twice, including bead 
beating accomplished with the FastPrep®-96 (MP) instrument and incubation at 95 ˚C for ten 
minutes. Proteinase K was added using two concentrations after the first RBB procedure and 
incubated at 70 ˚C for 10 min. Finally, the DNA was extracted using the KingFisher FLEX 
(Thermo scientific) instrument. The DNA concentration of the extracted samples was 
determined using the high sensitivity Quant-iT™ dsDNA assay kit (Molecular Probes). The 
fluorescence was measured with the FLUOstar Optima plate reader (BMG LABTECH).  
The samples extracted with both the RBB method and the RBB + proteinase K were run with 
qPCR to determine the difference between the methods. In qPCR, 1 ng of each primer was used 
[22], 10 μl of 2x BioRad iQ™ SYBR® Green Supermix, 5 ng DNA and addition of water to 
get the final volume of 25 μl for each reaction. The qPCR was performed in the BioRad CFX96 
Touch™ instrument. No difference was observed in the DNA yield from the extraction, nor 
from the qPCR results and the study was therefore completed using the RBB extraction method 
without the addition of proteinase K. 
Library preparation 
The fungal DNA was amplified with the PCR primer pair ITS1F (FWD, 
CTTGGTCATTTAGAGGAAGTAA) and ITS2 (REV, GCTGCGTTCTTCATCGATGC), 
which have been verified to target the conserved ITS region of fungal DNA [22] and proved to 
work more successfully than the other possible primer pairs [17]. The library preparation 
protocol was optimized by using different conditions in the PCR protocol for optimal product 
gain. In the final protocol, the library was prepared in a three-step PCR, where the ITS1 region 
first was amplified with the ITS1F an ITS2 primers mentioned. In the second PCR, the PCR 
product from the initial PCR reaction was amplified using ITS1F (FWD, 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTTGGTCATTTAGAGGAAGTAA) 
and ITS2 (REV, AGACGTGTGCTCTTCCGATCTGCTGCGTTCTTCATCGATGC) primers 
with Illumina adapters for MiSeq sequencing. The PCRs were carried out using a BioRad 
T100™ Thermal Cycler using the following conditions: denaturation at 98 ˚ C for 60 s, 44 cycles 
at 98 ˚C for 10 s, 58 ˚C for 40 s, and 72 ˚C for 40 s, followed by a final extension time of 10 
min at 72 ˚C. In the reaction mixture, 2x Phusion High-Fidelity PCR Master Mix with HF 
Buffer (ThermoFisher Scientific), 2 μl of each primer (5 μM), and 0.6 μl DMSO was used. 
Water was added to get a final volume of 20 μl for each reaction. For the initial PCR reaction, 
5 ng DNA was used. In the following PCR reaction, 4.4 μl of the initial PCR product was used 
directly as template. After the second PCR, the product was purified using AMPure XP beads 
(Beckman Coulter, Copenhagen, Denmark) according to the 16S metagenomic library prep 
guide using 0.8x concentration of beads [23]. The purified products were analyzed using 
LabChip® GX Touch™ nucleic acid analyzer. The DNA concentrations of the samples were 
measured with the Quant-It PicoGreen dsDNA Assay Kit. The absorbance was measured using 
the FLUOstar plate reader. In the third PCR reaction, barcodes for sequencing were added to 
the samples by index PCR, primers previously published [24]. The PCR products were purified 
with AMPure XP beads, as previously, and analyzed with LabChip. The concentrations were 
measured again as previously. Finally, the samples were pooled for MiSeq sequencing by 
adding 10 nM of each sample to the pool.  
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Analysis of sequencing data 
The MiSeq sequencing data was preprocessed using the mare package (Microbiota analysis in 
R made easily, [25]) in R [26]. Only forward reads were included in the analysis due to poor 
quality of reverse reads. The processing of the forward reads was done with the “ProcessReads” 
function included in the mare package and the default parameters in mare were used. The reads 
were truncated to 150 nt to exclude to low quality region of the reads. Reads below the 
abundance of 0.00001% were discarded. USEARCH 8 [27] was used to dereplicate reads and 
to remove chimeras for annotation using the unite database for fungi [28]. Low quality reads 
were discarded from further analysis. The reads were clustered to operational taxonomic units 
(OTUs) using USEARCH8 [27], after which richness and diversity [29] were assigned for the 
samples. Further analysis was completed using visualization tools included in mare [25].  
ASCA IgG/IgA ELISA assay 
IgG and IgA anti-Saccharomyces cerevisiae antibody (ASCA) concentrations were measured 
from IBD serum samples using a commercialized ELISA assay (ASCA IgG/IgA ELISA, 
Demeditec Diagnostics GmbH). The serum samples were diluted to 1:100, as recommended by 
the manufacturer, and were analyzed as singlicates for both IgG and IgA ELISA assays. Plates 
were read at 405 nm by the Hidex Sense Microplate Reader. The OD 405 nm values were 
analyzed by comparison to the standards included in the kit. Values exceeding or equal to 10 U 
ml-1 were considered as positive outcomes, as recommended by the manufacturer. 
Calprotectin ELISA assay 
The calprotectin concentration of IBD patient serum samples was measured with the ELISA 
sandwich method using two combinations of antibodies (Anti-human Calprotectin 3406 and 
3407 SPTN-5, Medix Biochemica) to capture the calprotectin. The two antibody-combinations 
used were: 3407-3407 and 3406-3407, as recommended by the manufacturer. The samples 
measured in the ELISA assay were IBD serum samples taken before the start of infliximab 
therapy and twelve weeks after infliximab therapy and the samples were analyzed as duplicates. 
As standard, Recombinant Calprotectin Antigen (Medix Biochemica) was used starting from a 
concentration of 300 ng ml-1 and diluted 1:3 in blocking buffer (TRIS-CaCl2-0.5% BSA, pH 8). 
One of the samples had previously been determined to have a high calprotectin concentration 
and was used as a control.  
Shortly, the ELISA plates were coated with 100 μl primary antibody (2 μg ml-1, dilution in 
PBS) and incubated at +4 ˚C overnight. The fluid was then discarded, the wells were washed 
with 250 μl of washing buffer (100 mM TRIS-10 mM CaCl2-0.05% Tween-20, pH 8) once, 
blocked with 200 μl of blocking buffer (100 mM TRIS-10 mM CaCl2-0.5% BSA, pH 8) and 
incubated for approximately 1 h at room temperature. The plates were washed twice with 250 
μl of washing buffer, the serum samples were diluted to 1:20 in blocking buffer and 100 μl of 
the dilution was added to each well. The plates were then incubated for approximately 1 h at 
room temperature with rotation. The plates were washed three times with 250 μl washing buffer, 
the secondary antibody was diluted to 1:3000 in blocking buffer and 100 μl was added to each 
well. The plates were then incubated as after the addition of serum. The plates were washed 
five times with 250 μl washing buffer and 100 μl substrate solution (para-
nitrophenylphosphatase dissolved in 1M diethanolamine, 0.5 mM MgCl2) was added. When 
the colors changed to a linear range, the reaction was stopped using 100 μl 1M NaOH, and the 
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plates were finally read at 405 nm with Hidex Sense Microplate Reader. The OD 405 nm values 
were compared to those of the standards. The results were analyzed by first normalizing the 
variation between the plates by calculating the average of the control of each plate separately 
and adjusting these to the same level. The sample values were then adjusted by this factor. 
RESULTS 
Patient characteristics 
A total of 73 IBD patients were included in this study, of whom 25 were diagnosed with CD, 
46 with UC, and 2 with IBDU. Of the total number of patients, 53% responded well to 
infliximab treatment, 26% responded partially, and 14% were not responsive at twelve weeks 
after the start of infliximab therapy. Patients in the non-responding group that underwent 
colectomy surgery, due to no sustained remission, were included. The number of patients 
included varied in the different assays (Table 1). Additional patient characteristics are presented 
in Table 1. 
Table 1. Basic characteristics of IBD patients 
 
*Patients that underwent colectomy before evaluating the drug response were included in the non-responders. 
Mycobiota characterization results 
In this study, the gut mycobiota in IBD patients was characterized through Illumina MiSeq 
sequencing to detect possible markers for drug response to infliximab. The total number of 
reads in each sample before preprocessing using the mare package [25] was at an average of 
approximately 54 700 reads. After processing, by using only forward reads, the average 
decreased to 4700 high quality reads in each sample. The two main phyla of fungi observed in 
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the mycobiota of IBD patients, when assigning taxonomy using the unite database [28], were 
Ascomycota and Basidiomycota. The most abundant genus in the gut mycobiota was Mucor 
for all IBD subtypes (Fig. 1). Other fungi present were of the genera Spiromyces, Grammothele, 
Laetisaria, Inocybe, Entoloma, Amanita, Candida, Saccharomyces, Clavispora, Geotrichum, 
Debaryomyces, Oididendron, Chrysosporium and Elaphomyces (Fig. 1). In Crohn’s disease 
patients, Candida was more abundant, whereas Saccharomyces was less abundant, compared 
to the other IBD subtypes (Fig. 1).  
 
Fig. 1. Gut mycobiota composition in IBD subtypes UC (ulcerative colitis), CD (Crohn’s disease) and IBDU 
(unclassified IBD). The plot presents the most abundant genera (mean abundance = 0.01), showing the relative 
abundance of the genera in each IBD subtype. The genera are color-coded and shown on the right side of the panel. 
The unidentified1-4 refer to four fungal taxa not assigned by the unite database. 
The gut mycobiota was studied according to response against infliximab therapy to compare 
the compositions between the groups. The same genera of fungi can be observed to be present 
in both responders and partial responders, part from the Clavispora genus, that is not present in 
the group of partial responders (Fig. 2). In the group of non-responders, the genus Geotrichum, 
present in both responders and partial responders, is not observed and the genus Spiromyces is 
more abundant compared to the other groups (Fig. 2). 
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Fig. 2. Gut mycobiota composition according to infliximab treatment response. R represents response, NR no 
response and PR partial response to infliximab therapy. The drug response was assigned to the patients at twelve 
weeks after the initiation of infliximab therapy. The plot presents the most abundant genera (mean abundance = 
0.01), showing the relative abundance of the genera in the response groups. The genera are color-coded and shown 
on the right side of the panel. The unidentified1-4 refer to four fungal taxa not assigned by the unite database. 
The gut mycobiota at genus level did follow the same pattern in the variation between IBD 
subgroups, when divided further according to response against infliximab (assigned at twelve 
weeks post infliximab therapy), apart from the genus Spiromyces, which was more abundant in 
Crohn’s disease patients not responding to infliximab, compared to the same IBD subtype that 
did respond, or responded partially to infliximab (Fig. 3).   
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Fig. 3. Gut mycobiota composition according to infliximab therapy response in IBD subtypes UC (ulcerative 
colitis), CD (Crohn’s disease) and IBDU (unclassified IBD). The plot presents the most abundant genera (mean 
abundance = 0.01), showing the relative abundance of the genera for the response groups. The drug response was 
assigned to the patients at twelve weeks after the initiation of infliximab therapy.  The genera are color-coded and 
shown on the right side of the panel. The unidentified1-4 refers to four fungal taxa not assigned by the unite 
database. 
The possible markers in the gut mycobiota were further investigated by studying the mycobiota 
composition at the timepoint before start of infliximab therapy for the response groups. At 
baseline, the non-responders had a higher abundance of the genera Candida and Spiromyces, a 
lower abundance of the genus Inocybe, and no Oididendron was present, compared to the 
responders and partial responders (Fig. 4). No difference in mycobiota composition according 
to IBD subtypes was observed when analyzing the subtypes using a principal coordinates 
analysis plot (Fig. 5). 
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Fig. 4. Gut mycobiota composition of IBD patients at baseline according to infliximab treatment. R represents 
response, NR no response and PR partial response to infliximab therapy. The drug response was assigned to the 
patients at twelve weeks after the initiation of infliximab therapy. The plot presents the most abundant genera 
(mean abundance = 0.01), showing the relative abundance of the genera in the response groups. The genera are 
color-coded and shown on the right side of the panel. The unidentified1-4 refers to four fungal taxa not assigned 
by the unite database.   
 
Fig. 5. Principal coordinates analysis (PCoA) plot according to IBD subtypes based on Bray-Curtis dissimilarity. 
The background color indicates interpolated values of diversity. The IBD subtypes are number-coded on the right 
side of the panel where 1 equals UC, 2 equals CD, and 3 equals IBDU. 
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ASCA IgG/IgA ELISA assay results 
The association between ASCA concentrations and response to infliximab treatment was 
studied to find differences between the response groups. This was achieved by analyzing IgG 
and IgA antibodies against ASCA in baseline serum samples from 69 prospective IBD patients 
using ELISA. Positive IgG values were observed in 29% and positive IgA values in 14% of the 
total number of patients. In patients suffering from Crohn’s disease, the positive values were 
59% of the IgG and 36% of the IgA values. In ulcerative colitis patients, however, the positive 
outcome was 14% of the IgG and 2% of the IgA values (Table 2).  
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Fig. 7. Serum ASCA IgG/IgA concentrations of IBD patients. In the plot, the ASCA values are presented for each IBD subtype (Crohn’s disease (CD) and ulcerative colitis 
(UC)) and also according to response against infliximab. The drug response was assigned at twelve weeks post infliximab therapy. The unclassified IBD patients, and the 
patients with undefined drug response at week 12 post infliximab were excluded from the ASCA IgG/IgA data. Values exceeding 10 U ml-1 were considered positive and this 
is indicated with a line in the figure.
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Table 2. Serum ASCA IgG/IgA values of IBD patients at baseline 
 
IFX response = response to infliximab therapy at twelve weeks post treatment. IgG pos (%) = the percentage of 
positive IgG values. IgA pos (%) = the percentage of positive IgA values. 
For finding possible connections between concentration of ASCA and the presence of S. 
cerevisiae in the gut mycobiota, the association between ASCA values and the abundance of 
Saccharomyces family in the mycobiota was explored. However, no correlation between ASCA 
IgG/IgA values and Saccharomycetaceae or Saccharomycetales relative abundances (calculated 
from read counts of organized family table created by the R package mare [25]) were observed 
(Spearman test, r = -0.020, p = 0.871 for IgG, and r = -0.173 p = 0.265 for IgA, n = 68). 
Calprotectin ELISA assay results 
In the calprotectin ELISA assay two antibody combinations were used for measuring the serum 
calprotectin by targeting the S100A8/A9 protein complex of calprotectin in baseline samples 
and 12-week post infliximab samples in 71 prospective IBD patients. This was done to 
investigate the correlation between serum calprotectin and fecal calprotectin values. For 
antibody combination 3406-3407, the serum calprotectin values were higher (P=0.0124) before 
the start of infliximab therapy in CD patients (933±428 ng ml-1 (mean±standard deviation)) 
than 12-weeks post infliximab (727±275 ng ml-1). The values follow the same pattern for UC 
patients (P<0.0001) with significantly higher values (1167±437 ng ml-1) before treatment than 
post treatment (746±442). In the only unresponsive CD patient with serum samples collected 
at both timepoints, the serum calprotectin value was higher 12-weeks post infliximab than 
before the start of medication for both antibody combinations used in ELISA (Fig. 8).  
15 
 
pr
e 
IF
X
po
st
 IF
X 
(1
2)
 CD
Responders
pr
e 
IF
X
po
st
 IF
X 
(1
2)
CD Partial
 Responders
pr
e 
IF
X
po
st
 IF
X 
(1
2)
 CD
Non-Responders
pr
e 
IF
X
po
st
 IF
X 
(1
2)
pr
e 
IF
X
po
st
 IF
X 
(1
2)
0
500
1000
1500
2000
All CD
S
e
ru
m
 C
a
lp
ro
te
c
ti
n
 (
n
g
/m
l)
pr
e 
IF
X
po
st
 IF
X 
(1
2)
0
500
1000
1500
2000
2500
S
e
ru
m
 C
a
lp
ro
te
c
ti
n
 (
n
g
/m
l)
pr
e 
IF
X
po
st
 IF
X 
(1
2)
pr
e 
IF
X
po
st
 IF
X 
(1
2)
Serum calprotectin ELISA antibody combination 3406-3407
All UC UC RE UC PR UC NR
 
Fig. 8. Serum calprotectin values of IBD patients before and after infliximab therapy measured by ELISA using 
3406-3407 antibody combination. All CD: all Crohn’s disease patients. CD responders: all Crohn’s disease patients 
responding, CD partial responders: all Crohn’s disease patients responding partially, and CD non-responders: all 
Chron’s disease patients not responding to infliximab at twelve weeks post the start of treatment. Identically, All 
UC: all ulcerative colitis patients, UC RE: ulcerative colitis patients responding to treatment, UC PR: ulcerative 
colitis patients responding partially to treatment, UC NR: ulcerative colitis patients not responding to treatment. 
Pre IFX shows the calprotectin values before the start of infliximab therapy and post IFX (12) shows the 
calprotectin values after twelve weeks post infliximab treatment. 
Similarly, for the antibody combination 3407-3407 the serum calprotectin values were higher 
in CD patients (p = 0.0597) before start of infliximab therapy (768±464) than after twelve weeks 
of infliximab treatment (648±447). Again, the UC patients had significantly higher serum 
calprotectin values (p = 0.0002) before start of infliximab therapy (1182±718) than twelve 
weeks post therapy (662±641). Identically as for the previous antibody combination, the only 
CD non-responder from whom serum samples has been collected at both timepoints showed 
higher post-infliximab value than before start of treatment (Fig. 9). 
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Fig. 9. Serum calprotectin values of IBD patients before and after infliximab therapy measured by ELISA using 
3407-3407 antibody combination. All CD: all Crohn’s disease patients. CD responders: all Crohn’s disease patients 
responding, CD partial responders: all Crohn’s disease patients responding partially, and CD non-responders: all 
Chron’s disease patients not responding to infliximab at twelve weeks post the start of treatment. Identically, All 
UC: all ulcerative colitis patients, UC RE: ulcerative colitis patients responding to treatment, UC PR: ulcerative 
colitis patients responding partially to treatment, UC NR: ulcerative colitis patients not responding to treatment. 
Pre IFX shows the calprotectin values before the start of infliximab therapy and post IFX (12) shows the 
calprotectin values after twelve weeks post infliximab treatment. 
No correlation was observed at baseline between serum calprotectin (antibody combinations 
3406-3407) and fecal calprotectin measured with reference ELISA (CalproLAB), nor at 12 
weeks after the start of infliximab therapy (Fig. 10.). The same pattern was determined for 
antibody combination 3407-3407 when comparing with fecal calprotectin measured with 
reference ELISA (CalproLAB) (Fig. 10.). Similarly, no correlation (p > 0.05) was observed at 
the same timepoints between the serum calprotectin (ab combinations 3406-3407 and 3407-
3407) and fecal calprotectin measured at HUSLAB (data not shown). 
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Fig. 10. Correlation between serum and fecal calprotectin values in IBD patients at baseline and 12-weeks post 
infliximab. In the plot, the correlations determined using Spearman correlation test are shown and the abbreviation 
AB represents antibody. 
DISCUSSION 
IBD is a common disease in the industrialized countries, but in recent years its prevalence has 
increased, and it has become a global health care problem [2, 3]. Although, no exact 
pathogenesis has been determined for IBD, it is known that genetics, gut microbiome and 
environmental factors play a major role in the development of the disease [4, 5]. The biological 
drug infliximab is given to the patients for whom the regular treatment is ineffective. However, 
approximately one third of the patients suffering from Crohn’s disease, and up to 50% of 
ulcerative colitis patients either do not respond to the treatment or lose response over time [10]. 
This is a concern, not only because of the high costs that the medication requires, but also 
because of the unnecessary side-effects that the ineffective drug causes to the patients. Finding 
predictive markers for drug response to infliximab is therefore of great importance. In the 
current study, this was achieved by characterizing the gut mycobiota of prospective IBD 
patients suffering from ulcerative colitis or Crohn’s disease by MiSeq sequencing. The cohort 
population in this study had a relatively large patient number, which allows for detailed 
experimental analysis. As supportive data, ASCA IgG and IgA values were measured from 
baseline serum samples, and calprotectin values were measured using two antibody 
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combinations from baseline and twelve weeks post infliximab treatment serum samples with 
ELISA. Previously, predictive markers for drug response to infliximab have been found when 
studying the gut microbiota [30, 31], but to this day, no previous studies have investigated the 
possible role of the mycobiota in drug response against infliximab. The findings of this study 
revealed that there is a shift in the gut mycobiota composition in the group of patients that do 
not respond to the infliximab therapy compared to the group of patients responding well, or 
partially, to the drug.  
The detected fungi of the gut mycobiota in IBD patients belonged to the phyla Ascomycota or 
Basidiomycota. Identically, it has been observed that IBD patients have a mycobiota 
composition consisting of these phylum [32, 33]. In this study, due to poor quality of reverse 
reads, only forward reads were included in the analysis and therefore the mycobiota was studied 
only at genus-level. As previously published; the most common genera in the gut mycobiota 
are Saccharomyces and Candida [17, 34, 32]. According to the results in this study, the most 
abundant genus was Mucor, the second most abundant genus was either Inocybe or Candida. 
Of the most abundant genera detected in this study, Saccharomyces, Debaryomyces, Candida, 
Mucor, and Debaryomyces have been observed in multiple previously published studies [35, 
36, 32, 34, 17]. Additionally, the genera Amanita, Clavispora, and Geotrichum have been 
detected in less than two published studies as previously reviewed [35]. Finally, in the most 
abundant genera present in the mycobiota of IBD patients, four unidentified genera were not 
identified in the database, and therefore remained unidentified in the results.  
In the gut mycobiota, an increased abundance of Spiromyces was observed at both baseline and 
when including all timepoints, especially in patients suffering from Crohn’s disease. This 
indicates possible markers in the species of the Spiromyces genus. Before the start of infliximab 
treatment, the composition between the group of patients not responding to infliximab differed 
from the group responding well or partially to infliximab. The non-responding groups had 
higher abundance of Candida and Spiromyces and lower abundance of Inocybe and 
Oididendron in comparison to the other groups. The infliximab treatment is known to down-
regulate inflammation in the gut and thereby restoring the normal gut epithelium [37], which 
suggests a possibility of altering the microbiome composition of the gut. The difference in the 
gut mycobiota composition between response-groups before the start of infliximab therapy 
observed in this study could indicate that the species of the gut mycobiota in non-responding 
individuals somehow prevents the drug from restoring the gut to normal, thereby making the 
drug inefficient.  
The ASCA IgG and IgA values were measured from baseline serum samples in IBD patients 
by ELISA to study whether there was a difference between the group responding well to 
infliximab therapy and the group of non-responders. No difference between responders and 
non-responders was observed, but the patients suffering from Crohn’s disease had higher ASCA 
values than the patients suffering from ulcerative colitis. These results are according to 
previously published data [14], and because of this fact, ASCA values are used as a diagnostic 
tool for Crohn’s disease.  
Fecal calprotectin concentrations are already used inflammatory marker in the gut. The serum 
calprotectin levels were explored to study whether serum calprotectin values can be used as a 
similar marker of gut inflammation as this would provide a more convenient sampling method 
for both the patient and diagnostics. Serum calprotectin levels were measured by ELISA for 
comparison with the fecal calprotectin levels already measured with reference ELISA. There 
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was no correlation observed between the fecal calprotectin concentrations and the serum 
calprotectin levels neither at baseline nor at twelve weeks post infliximab and this has also 
previously been observed, using different antibodies [16]. However, the calprotectin 
concentrations did decrease when comparing the levels at twelve weeks to the levels at baseline. 
These results follow the pattern of fecal calprotectin levels, suggesting the serum calprotectin 
levels working more as a marker of systematic inflammation, as previously reported [38, 39, 
40], and, thus, cannot be used as an inflammatory marker of the gut.  
 
As previously reviewed [36], the choice of primers, and particularly the choice of database and 
pipelines for analysis of data highly impact the results of a mycobiome study. The primers 
amplifying the ITS1 region was used in this study, and as previously stated [36, 17], this should 
be working sufficiently for this particular purpose. This primarily leaves the choice of analysis 
pipeline and database for further investigation. In this study, the mare package [25] and the 
UNITE database [28] was used for analysis of sequencing data. Different pipelines have been 
compared for the analysis of 16S sequencing data previously [41] and no difference was 
observed. In the mare package [25], comparison between mare and QIIME [42] is included, 
and mare has been proved to be work better for 16S data analysis specifically. The mare package 
was chosen based on this, in addition to the inbuilt statistical analysis tools, but it is developed 
for analysis of bacterial data, and therefore it might not be optimal for the analysis of ITS 
sequencing data. In addition, databases for assigning taxonomy should be compared for optimal 
results. This could be the reason to the four unidentified genera appearing in the plots, and to 
the most abundant genera in this study, that has not been detected in other studies of the human 
gut mycobiota. Another alarming outcome in the processing phase using the mare package was 
the massive decrease of reads passing through the filters. This is partially due to high levels of 
A-nucleotides added to the short reads in the sequencing due to differing lengths of reads, but 
it is my conclusion that the inbuilt filtering in mare is too strict for ITS-processing thereby 
causing the massive decrease of read numbers. Furthermore, the diverging results gained in this 
study suggests reason to question the trustworthiness of the output until comparison between 
pipelines and databases have been completed. After re-evaluation of the analysis methods, the 
mycobiota results should be analyzed together with the ASCA results to verify the correlation 
between Saccharomycetales and ASCA values. 
Other pipelines that can be used for analysis of ITS sequencing data are the QIIME pipeline 
[42, 34], DADA2 pipeline [43], BROCC pipeline [44], and CloVR-ITS pipeline [45]. The mare 
package [25] is proved to work well for analysis of 16S data, as previously mentioned [46] and 
in the mare package, USEARCH8 [27] is used for assigning OTUS and processing reads. In 
other pipelines, such as DADA2 [35] and QIIME [42], this is achieved using different tools. 
Both QIIME and DADA2 pipelines offer a specific workflow for processing of ITS data, which 
seems logical because of the difference between 16S and ITS sequencing data. The results 
gained by using the UNITE database [28] for assigning taxonomy should also be compared by 
using other databases such as BLAST [47]. To conclude, I believe that ITS data must be 
processed differently compared to 16S data, and therefore, the usage of the mare package in 
such is not optimal, and an ITS specific pipeline is therefore crucial for the analysis.  
In conclusion, differences in the gut mycobiota in the non-responding group, compared to the 
group responding well when studying the composition at all timepoints, and particularly at 
baseline, were observed. Based on this study, the variations of composition presented in the 
mycobiota could present predictive markers for drug response to infliximab therapy. More 
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detailed studies are required to specify the study, including using a pipeline optimized for the 
analysis of ITS data, studying the gut microbiota, virobiota and eucaryota from the same 
patients studied here, and further investigate the interaction between the microorganisms, of 
which the importance previously has been stated [48]. In addition, the gut mycobiota should be 
studied at species-level to further specify the markers and finally, to gain a more detailed 
composition of the fecal panel that would provide a predictive diagnostic tool for healthcare 
use. 
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